UBS raised the firm’s price target on Tenet Healthcare (THC) to $260 from $238 and keeps a Buy rating on the shares. The firm updated its model following the Q3 earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $232 from $225 at Morgan Stanley
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA